

## HR 3288

### Access to Prescription Digital Therapeutics Act of 2025

**Congress:** 119 (2025–2027, Current)

**Chamber:** House

**Policy Area:** Health

**Introduced:** May 8, 2025

**Current Status:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

**Latest Action:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (May 8, 2025)

**Official Text:** <https://www.congress.gov/bill/119th-congress/house-bill/3288>

### Sponsor

**Name:** Rep. Hern, Kevin [R-OK-1]

**Party:** Republican • **State:** OK • **Chamber:** House

### Cosponsors (9 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Thompson, Mike [D-CA-4]	D · CA		May 8, 2025
Rep. Craig, Angie [D-MN-2]	D · MN		May 20, 2025
Rep. Balderson, Troy [R-OH-12]	R · OH		Jul 2, 2025
Rep. Van Duyne, Beth [R-TX-24]	R · TX		Jul 14, 2025
Rep. Wittman, Robert J. [R-VA-1]	R · VA		Sep 9, 2025
Rep. Panetta, Jimmy [D-CA-19]	D · CA		Sep 26, 2025
Rep. DelBene, Suzan K. [D-WA-1]	D · WA		Oct 8, 2025
Rep. Sewell, Terri A. [D-AL-7]	D · AL		Dec 9, 2025
Rep. Ross, Deborah K. [D-NC-2]	D · NC		Mar 3, 2026

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	May 8, 2025
Ways and Means Committee	House	Referred To	May 8, 2025

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
119 S 1702	Related bill	<b>May 8, 2025:</b> Read twice and referred to the Committee on Finance.

### **Access to Prescription Digital Therapeutics Act of 2025**

This bill provides for Medicare and Medicaid coverage of prescription digital therapeutics (i.e., software applications that are used to prevent, manage, or treat medical conditions). The Centers for Medicare & Medicaid Services must establish a Medicare payment methodology for payments to manufacturers that takes into account certain factors (e.g., ongoing use); manufacturers must report specified information about private payors, subject to civil penalties.





